Dose responsive PD/PK relationship of GSK2110183 and GSK2141795 in BT474 tumor xenografts.
- Melissa Dumble (590493)
- Ming-Chih Crouthamel (590494)
- Shu-Yun Zhang (590495)
- Michael Schaber (590496)
- Dana Levy (590497)
- Kimberly Robell (590498)
- Qi Liu (33068)
- David J. Figueroa (590499)
- Elisabeth A. Minthorn (590500)
- Mark A. Seefeld (590501)
- Meagan B. Rouse (590502)
- Sridhar K. Rabindran (590503)
- Dirk A. Heerding (590504)
- Rakesh Kumar (8432)
Publication date
June 2014
DOIAbstract
<p>Mice bearing BT474 tumors were treated with vehicle or GSK2110183 at 10, 30 or 100/kg (A) or GSK2141795 at 3, 10 and 30 mg/kg (B) daily for 7 days (QDx7; n = 3/group). Tumors were harvested and analysed by ELISA for phosphorylated and total PRAS40 levels. The concentration of compound in the tumor (black triangles; ng/g) and blood (grey squares; ng/mL) was quantified by LC/MS-MS. Data represents mean ± s.d. *p<0.01.</p
Add to ORKG